Kihara James's Form 4 filing
Acadia Pharmaceuticals Inc (ACAD) · filed May 19, 2025
- Accession no.
- 0001415889-25-013742
- Filed
- May 19, 2025
- Trade date
- May 16, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $90.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kihara JamesCIK 0001816160 | Officer (PRINCIPAL ACCOUNTING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | SSaleDisposed | −2,000 | $25.00 | −$50,000 | 22,395 | Direct | |
| May 16, 2025 | Common Stock | SSaleDisposed | −2,000 | $20.00 | −$40,000 | 20,395 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.